Gujarat Terce Laboratories Ltd (GUJTERC) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Gujarat Terce Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Gujarat Terce Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve The Unaudited Standalone ....
Intimation · 05 Nov 2026, 5:30 am
Gujarat Terce Laboratories Board to Consider Q2 and H1 FY27 Results on 5th Nov'26 Gujarat Terce Laboratories Limited has scheduled a Board of Directors meeting on 5th Nov'26 to consider and approve the unaudited standalone financial results for the second quarter and half year ended 30th Sep'26, subject to a limited review by statutory auditors. In compliance with insider trading regulations, the company's trading window for dealing in its securities remains closed from 1st Oct'26 until 7th Nov'26, concluding 48 hours post the declaration of the financial results.
Detailed disclosure is attached
Annual General Meeting · 21 Aug 2026, 11:38 pm
Gujarat Terce Labs AGM: All Resolutions Passed With Requisite Majority At its 41st AGM on 21 Aug'26, Gujarat Terce Laboratories shareholders approved all four proposed resolutions with a requisite majority. Total voter turnout was 44.55%, representing 3,470,935 shares. Key resolutions included adopting FY26 financial statements, re-appointing Natwarbhai Prajapati as a Director, re-appointing Aalap Prajapati as MD & CEO until 27 Oct'29, and ratifying remuneration for Cost Auditors M/s. K V M & Co for FY27. All resolutions received 100% of votes cast in favour, with no votes against.
Detailed disclosure is attached.
Annual General Meeting · 21 Aug 2026, 9:53 pm
Gujarat Terce Laboratories: Key Resolutions Passed at 41st AGM At its 41st Annual General Meeting on 21st Aug'26, Gujarat Terce Laboratories passed all agenda items with the requisite majority. Key resolutions included the adoption of standalone financial statements for the year ended 31st Mar'26 and the re-appointment of Mr. Natwarbhai Prajapati as a Director. A special resolution was passed to re-appoint Mr. Aalap Prajapati as Managing Director & CEO for a three-year term, effective from 28th Oct'26. The meeting was attended by 38 shareholders via video conference.
Detailed disclosure is attached.
Change in Management · 21 Aug 2026, 9:42 pm
Gujarat Terce Laboratories Re-Appoints Aalap Prajapati as MD & CEO Gujarat Terce Laboratories has re-appointed Mr. Aalap Prajapati as Managing Director & CEO for a three-year term, effective from 28 Oct'26 to 27 Oct'29. The approval was granted at the 41st AGM on 21 Aug'26. Mr. Prajapati has over 15 years of experience in the pharmaceutical sector, specializing in strategy, operations, and business development. He is the son of Mr. Natwarbhai Prajapati, the company's Whole-Time Director. This move signals leadership continuity and a continued focus on operational efficiency and growth initiatives.
Corrigendum/Revised intimation regarding Re-appointment of Managing Director & Chief Executive Officer of the Company- Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) ....
Change in Management · 21 Aug 2026, 9:34 pm
Gujarat Terce Corrects MD & CEO Re-appointment Tenure Gujarat Terce Laboratories has corrected the tenure for the re-appointment of Mr. Aalap Prajapati as MD & CEO. An earlier intimation on 29 May'26 mistakenly stated a five-year term. The company now clarifies the correct tenure is three years, effective from 28 Oct'26 to 27 Oct'29. This revision was approved by shareholders at the 41st AGM on 21 Aug'26. Mr. Prajapati has over 15 years of pharmaceutical industry experience and is the son of Whole-Time Director, Mr. Natwarbhai Prajapati.
Detailed disclosure is attached.
Outcome · 07 Aug 2026, 10:21 pm
Gujarat Terce Reports Q1FY27 Loss Amidst Revenue Decline Gujarat Terce Laboratories reported a net loss of Rs. 17.81 lakhs for Q1FY27, a significant downturn from a Rs. 10.10 lakh profit in Q4FY26 and a Rs. 4.35 lakh loss in Q1FY26. Total revenue for the quarter ended 30 Jun'26 fell 13.4% YoY to Rs. 948.47 lakhs. The loss was driven by a 17% YoY decline in revenue from operations. Total expenses decreased by 12.6% YoY to Rs. 963.35 lakhs. Consequently, basic EPS stood at Rs. -0.23, compared to Rs. -0.06 in the prior year's quarter.
Detailed disclosure is attached.
Financial Result · 07 Aug 2026, 10:14 pm
Gujarat Terce Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 900 (-17.1% YoY | -21.0% QoQ) ■ EBITDA: -49.3 (-2316.7% YoY | Profit to Loss QoQ) ■ EBITDA Margin (%): -5.5 (-529 bps YoY | Profit to Loss QoQ) ■ PAT: -17.8 (-309.4% YoY | Profit to Loss QoQ) ■ EPS (INR): -0.23 (-283.3% YoY | Profit to Loss QoQ)
Gujarat Terce Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Intimation · 07 Aug 2026, 5:30 am
Gujarat Terce Laboratories Sets Board Meeting for Q1FY27 Results on 7 Aug'26 Gujarat Terce Laboratories has scheduled a Board of Directors meeting on Fri, 7 Aug'26, to consider and approve the Unaudited Standalone Financial Results for the first quarter ending 30 Jun'26. The results will be subject to a limited review by the statutory auditor. In line with this, the company's trading window for insiders will remain closed from 1 Jul'26 to 9 Aug'26 (inclusive).
41st AGM of the shareholders of Gujarat Terce Laboratories Limited will be held on 21st August, 2026 at 12:00 noon through Video Conferencing or any other Audio-Visual Means facility
Annual General Meeting · 29 Jul 2026, 3:08 am
Annual Report for FY: 2025-26 is attached.
Others (Uncategorized) · 29 Jul 2026, 1:54 am
Detailed disclosure is attached.
Investor Presentation · 03 Jun 2026, 10:11 pm
Gujarat Terce Q4 FY26: Revenue Declines But Net Profit Turns Positive Gujarat Terce Laboratories reported challenging Q4 FY26 results, with revenue declining 8% YoY to ₹1,139.93 lacs. EBITDA fell sharply by 68% to ₹36.93 lacs, compressing the EBITDA margin to 3.24% from 9.25% in Q4 FY25. Despite the top-line and operational weakness, the company posted a positive PAT of ₹10.1 lacs, a significant turnaround from a loss of ₹339.14 lacs in the prior year's quarter. For the full year FY26, revenue decreased 5% to ₹4,747.27 lacs, while PAT improved to ₹220.17 lacs.
The amended code is enclosed.
Others (Uncategorized) · 01 Jun 2026, 11:58 pm
Gujarat Terce Laboratories Amends Insider Trading Disclosure Code On 1 Jun'26, Gujarat Terce Laboratories (BSE: 524314) notified the exchange of an amendment to its Code of Fair Disclosure of Unpublished Price Sensitive Information. This update aligns the company's internal policies with recent changes to the SEBI (Prohibition of Insider Trading) Regulations, 2015. The revised code, effective from 29 May'26, reinforces protocols for handling and disseminating price-sensitive information to ensure regulatory compliance and fair disclosure practices. This is a standard corporate governance update.
Detailed disclosure is attached
Annual General Meeting · 30 May 2026, 10:05 pm
Gujarat Terce Laboratories Sets Annual General Meeting Date Gujarat Terce Laboratories Limited announced its 41st Annual General Meeting (AGM) will be held on Friday, 21 Aug'26. The Board of Directors confirmed the date during its meeting on 29 May'26. The cut-off date for determining member eligibility for e-voting and participation has been set for 14 Aug'26. This announcement pertains to regulatory disclosure requirements for the company listed on the BSE under security code 524314.
Detailed disclosure is attached
Annual General Meeting · 30 May 2026, 4:16 am
Gujarat Terce Q4 & FY26 Results; Board Approves MD & CEO Re-appointment Gujarat Terce Laboratories reported a Q4 FY26 net profit of ₹10.10 lakhs, down from ₹74.06 lakhs QoQ but recovering from a loss of ₹339.14 lakhs YoY. Revenue for the quarter was ₹1,147.59 lakhs. For the full year FY26, net profit was ₹220.17 lakhs, a significant turnaround from a loss of ₹97.87 lakhs in FY25, on revenue of ₹4,781.31 lakhs. An exceptional item of ₹45.39 lakhs for employee benefits impacted results. The Board also approved the re-appointment of Mr. Aalap Prajapati as MD & CEO.
Detailed disclosure is attached.
Outcome · 30 May 2026, 4:09 am
Gujarat Terce Q4 & FY26 Results: PAT Rebounds, One-Off Exceptional Item Reported Gujarat Terce Laboratories reported a profit of ₹220.17 lakhs for FY26, a significant turnaround from an FY25 loss of ₹97.87 lakhs. Full-year revenue declined 5.3% YoY to ₹4,781.31 lakhs. The company recorded a one-time exceptional item of ₹45.39 lakhs due to an increase in employee benefit provisions under new labour codes. For Q4FY26, PAT stood at ₹10.10 lakhs, down from ₹74.06 lakhs QoQ but recovering from a loss of ₹339.14 lakhs YoY. The board also approved the re-appointment of Aalap Prajapati as MD & CEO.
Detailed disclosure is attached.
Change in Management · 30 May 2026, 4:01 am
Gujarat Terce Labs Board Approves Re-appointment of MD & CEO Gujarat Terce Laboratories' Board approved the re-appointment of Mr. Aalap Prajapati as Managing Director & CEO on 29 May'26. The new five-year term is effective from 28 Oct'26 to 27 Oct'31, pending shareholder approval. Mr. Prajapati has over 15 years of pharmaceutical industry experience and is the son of the company's Whole-Time Director, Mr. Natwarbhai Prajapati. The appointment aligns with the Nomination and Remuneration Committee's recommendation and is subject to shareholder approval at the 41st AGM.
Detailed disclosure is attached
Financial Result · 30 May 2026, 3:54 am
Gujarat Terce Laboratories Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 1,140 (-7.5% YoY | -7.3% QoQ) ■ EBITDA: 74.2 (-29.6% YoY | -34.8% QoQ) ■ EBITDA Margin (%): 6.5 (-204 bps YoY | -275 bps QoQ) ■ PAT: 10.1 (Loss to Profit YoY | -86.4% QoQ) ■ EPS (INR): 0.13 (Loss to Profit YoY | -86.3% QoQ)
Gujarat Terce Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve the Annual Audited ....
Intimation · 27 May 2026, 5:30 am
Gujarat Terce Laboratories Board Meeting Set for 27 May'26 Gujarat Terce Laboratories has scheduled a Board of Directors meeting on 27 May'26 to consider and approve the audited standalone financial results for Q4 FY26 and the full financial year ending 31 Mar'26. The agenda also includes matters related to the upcoming Annual General Meeting. In accordance with insider trading regulations, the trading window for company securities is closed from 1 Apr'26 through 29 May'26.
Detailed disclosure attached
Others (Uncategorized) · 24 Feb 2026, 11:04 pm
Gujarat Terce Labs: BSE Approves Trading of 371k Shares from Warrant Conversion Gujarat Terce Laboratories received trading approval from the BSE for 3,71,000 new equity shares, effective from 25 Feb'26. The shares, with a face value of Rs. 10/-, were issued at a premium of Rs. 27.70/- each, resulting from the conversion of warrants allotted to promoter Mr. Aalap Prajapati on a preferential basis. This action will increase the company's listed share capital and potentially lead to equity dilution. The newly listed shares bear distinctive numbers from 74,20,301 to 77,91,300.
Investor Presentation for third quarter and nine months ended on 31 December 2025
Investor Presentation · 04 Feb 2026, 10:21 pm
Gujarat Terce Q3 FY26: Margin Expansion Despite Revenue Dip Gujarat Terce Laboratories reported a mixed Q3 FY26 performance. While revenue declined 3% YoY to ₹1,229.35 lacs due to a strategic rationalization of low-margin businesses, EBITDA grew 8% to ₹124.86 lacs. This was driven by improved operational efficiencies, expanding the EBITDA margin to 10.16% from 9.13% a year ago. However, Reported PAT fell 27% YoY to ₹74.06 lacs, with EPS dropping to ₹0.95 from ₹1.36. For 9M FY26, revenue was down 4.75% while EBITDA rose 6.78% YoY.
Detailed disclosure is attached
Financial Result · 04 Feb 2026, 10:14 pm
Gujarat Terce Labs Posts Lower Q3 Net Profit Amid Reduced Revenue Gujarat Terce Laboratories reported a Q3 FY26 net profit of ₹76.11 Lakhs, a 24.5% decrease YoY from ₹100.80 Lakhs, and down 45.8% QoQ. Revenue from operations for the quarter stood at ₹1,229.35 Lakhs, a slight decline of 3.1% YoY and 4.9% QoQ. Total expenses decreased to ₹1,129.21 Lakhs from ₹1,177.04 Lakhs YoY. For the nine months ended 31 Dec'25, net profit was ₹211.05 Lakhs, down 12.5% YoY from ₹241.26 Lakhs in the previous year. Basic EPS for Q3 was ₹0.95.
Outcome of the Board Meeting held on 4 February 2026 - Unaudited Standalone Financial Results of the Company for the third quarter and nine months ended 31 December 2025
Outcome · 04 Feb 2026, 10:06 pm
GUJARAT TERCE LABORATORIES LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 1229 (-3.1% YoY | -4.9% QoQ) ■ EBITDA: 114 (+4.3% YoY | -39.8% QoQ) ■ EBITDA Margin (%): 9.3 (+65 bps YoY | -536 bps QoQ) ■ PAT: 76.1 (-24.5% YoY | -45.8% QoQ) ■ EPS (INR): 0.95 (-26.4% YoY | -47.2% QoQ)
This is to inform that the name of the Company''s Statutory Auditor, M.A. Shah & Co. has been changed to Shah Doshi Patel & Associates LLP.
Change in Auditor · 04 Feb 2026, 9:59 pm
Gujarat Terce Laboratories Announces Statutory Auditor Name Change Gujarat Terce Laboratories (BSE: 524314) announced on 4 Feb'26 that the name of its Statutory Auditor has changed. The auditor, previously known as M.A. Shah & Co., will now operate under the new name Shah Doshi Patel & Associates LLP. The company confirmed that all other details of the Statutory Auditor remain unchanged. This administrative update does not signal a change in the auditing firm itself, only its registered name.
Gujarat Terce Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2026 ,inter alia, to consider and approve Unaudited Financial ....
Intimation · 04 Feb 2026, 5:30 am
Gujarat Terce Laboratories Sets Board Meeting for Q3 FY26 Results Gujarat Terce Laboratories will hold a Board Meeting on 4 Feb'26 to consider and approve the unaudited standalone financial results for the third quarter and nine months ending 31 Dec'25. In connection with this, the trading window for insiders will be closed from 1 Jan'26 to 6 Feb'26, inclusive.
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aalap Natubhai Prajapati
Others (Uncategorized) · 17 Dec 2025, 9:58 pm
Gujarat Terce: Promoter Increases Stake via Warrant Conversion Aalap Natubhai Prajapati, Promoter & MD of Gujarat Terce Laboratories, acquired 3,71,000 equity shares on 16 Dec'25. The acquisition resulted from the conversion of warrants initially allotted on a preferential basis on 01 Jul'24. This transaction, exempt from an open offer under SEBI SAST regulations, increased his shareholding from 9,80,827 shares (13.22%) to 13,51,827 shares (17.35%). This represents a significant 4.13 percentage point increase in the promoter's stake in the company.